ABACAVIR and LAMIVUDINE 600 mg/1 (ABACAVIR and LAMIVUDINE TABLET, FILM COATED) 600 mg/1

Abacavir and Lamivudine 600 mg/1 is a combination medication used to manage HIV infection. This oral tablet is designed to support antiviral therapy, helping to control the virus in the body.

Strength

600 mg/1

Pack Size

1 BOTTLE in 1 CARTON (31722-838-30) / 30 TABLET, FILM COATED in 1 BOTTLE

Manufacturer / TM Owner

Camber Pharmaceuticals, Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Abacavir and Lamivudine 600 mg/1 is primarily used in the treatment of HIV infection. This combination therapy works by reducing the amount of HIV in the body, which helps to improve the immune system and reduce the risk of HIV-related illnesses. It is often prescribed as part of a broader antiretroviral treatment plan.

Side Effects

Common effects of Abacavir and Lamivudine 600 mg/1 may include headaches, nausea, and fatigue. Some individuals might experience skin rashes or fever. These effects vary and are not experienced by everyone taking the medication.

Precautions & Warnings

It is important to inform your healthcare provider about any allergies or medical conditions before starting Abacavir and Lamivudine 600 mg/1. Regular monitoring and follow-up are recommended to ensure the medication is working effectively and to manage any potential side effects.

Avoid Interactions

Abacavir and Lamivudine 600 mg/1 may interact with other medications, including certain antiviral drugs and immune system suppressants. Always consult a healthcare provider before combining this medication with other treatments to avoid potential interactions.

Frequently Asked Questions

Abacavir and Lamivudine 600 mg/1 is used to manage HIV infection by reducing the amount of virus in the body.

This medication is taken orally, typically as directed by a healthcare provider. Always follow the prescribed dosage and administration instructions.

Common side effects may include headaches, nausea, and fatigue. Some individuals might experience skin rashes or fever.

It may interact with other medications, so consult a healthcare provider before combining it with other treatments.

It is important to inform your healthcare provider about any allergies or medical conditions before starting this medication.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.